← Back

Chengdu Easton Biopharmaceuticals Co Ltd

Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of pharmaceutical products in China and internationally. The company offers active pharmaceutical ingredients; finished dosage forms, including capsules, tablets, and injections; pharmaceutical intermediates; biological drugs; and generic drugs. Its products are used in oncology, cardiovascular, neurology and psychiatry, anesthetic and analgesics, urinary, anti-inflammatory, anti-diabetes, anthelmintic, and antiemetic therapeutic categories. The company was founded in 2009 and is headquartered in Chengdu, China.

Price · split & dividend adjusted
News & notes moving 688513.CG
688513.CG▼

Yuandong Biopharma's 2026 interim net profit was 130 million yuan, down 4.99% year on year

Yuandong Biopharma released its 2026 interim report, with net profit attributable to the parent company of 130 million yuan, a decrease of 4.99% compared with the same period last year. Total operating revenue was 659 million yuan, up 0.68% year on year. Net cash inflow from operating activities was 167 million yuan, up 6.30% year on year, achieving growth for two consecutive years. The company's latest asset-liability ratio was 20.98%, gross margin was 76.36%, return on equity was 4.42%, and diluted earnings per share was 0.74 yuan. The company had 6,589 shareholders, and the top ten shareholders held 102 million shares, accounting for 57.54% of total share capital.
688513.CG ▼
Jiemian·5dRead more ▾
688513.CG▲

Yuan Dong Bio Receives Registration Certificate for Remimazolam Besylate for Injection, Becoming the First Domestic Generic Approval

Yuan Dong Bio announced that on July 16, 2026, it received the Drug Registration Certificate for Remimazolam Besylate for Injection approved and issued by the National Medical Products Administration, with a specification of 25 mg, approved under chemical drug category 4, making it the first domestic company to receive approval for this generic drug. The drug is a Class II psychotropic substance, indicated for sedation and anesthesia in non-tracheal intubation procedures or operations, as well as for the induction and maintenance of general anesthesia.
688513.CG ▲
Jiemian·42dRead more ▾
688513.CG▲

Sci-Tech Innovation Board Medical ETF Huaxia Gains Over 2.2%, Driven by Policy Tailwinds and Overseas Licensing in Innovative Drug Sector

The Sci-Tech Innovation Board Medical ETF Huaxia closed up 2.22% at 1.06 yuan, while the underlying SSE STAR Market Biomedical Index surged 2.38%. Among constituents, Medicilon rose 12.77%, Olymvax Biopharmaceuticals gained 11.54%, and YD Bio advanced 8.49%. Recent policy tailwinds continue to unfold, including optimized review and approval for cell and gene therapies and the initial inclusion of drugs in medical insurance and commercial insurance catalogues. Meanwhile, domestic innovative drug overseas licensing deals approached 100 billion US dollars in the first half of the year, blockbuster new drugs received intensive approvals, and some pharmaceutical companies reported positive half-year earnings forecasts, steadily improving industry fundamentals. Donghai Securities noted that the pharmaceutical and biomedical sector offers significant medium- to long-term investment value and recommended active positioning.
688202.CG ▲688319.CG ▲688513.CG ▲
Jiemian·48dRead more ▾
Biotech & Genomic Medicine▲

STAR Market Healthcare ETF Huaxia surges over 3.8%, net inflows for 10 consecutive days

The STAR Market Healthcare ETF Huaxia rose 3.86% to 1.08 yuan, with net inflows for 10 consecutive days, attracting a total of 135 million yuan. The SSE STAR Market Biomedical Index surged 3.93%, with constituent stocks Medici rising 15.28%, Yundong Biotech up 11.44%, and Olin Biotech up 10.38%. In news, the National Essential Medicines List 2026 edition added 165 new drugs, and in the first half of 2026, the total value of China's innovative drug out-licensing deals approached the 100 billion dollar mark. Nanjing Securities noted that with the upcoming WCLC and ESMO conferences, cutting-edge fields such as bispecific antibodies and antibody-drug conjugates will enter a period of intensive clinical data disclosure, accelerating the alignment of China's innovative drug valuation system with global standards.
688202.CG ▲688319.CG ▲688513.CG ▲
Biotech & Genomic Medicine ▲
Jiemian·48dRead more ▾
© 2026 MarketDXAsset